#USA #New York #Pomerantz LLP #Investor Claims #argenx

Pomerantz Law Firm Investigates Argenx SE Amid Investor Concerns

On November 5, 2026, the Pomerantz Law Firm announced an investigation into potential claims on behalf of investors in Argenx SE (NASDAQ: ARGX). The law firm is urging affected investors to reach out to Danielle Peyton for further information. This investigation comes in light of troubling reports regarding Argenx's recent decision to terminate a significant clinical trial.

The clinical study in question, known as the Phase 3 UNITY study, aimed to test the efficacy of efgartigimod—a treatment for moderate-to-severe Sjögren's disease. Unfortunately, on October 8, 2026, Argenx revealed that it would discontinue the trial following unfavorable recommendations from an Independent Data Monitoring Committee (IDMC). The committee concluded that the study was unable to achieve its primary endpoint, which raised substantial concerns about Argenx's business practices and transparency.

As a direct consequence of this announcement, Argenx's stock price took a sharp decline, plummeting by $109.81 per share, or 11.83%, closing at $818.63 on the day of the press release. This significant drop in stock value has left many investors feeling uncertain and has prompted further scrutiny into the company's operational integrity.

Pomerantz LLP, which has built a reputation as one of the leading law firms in the corporate and securities litigation space, is well-known for representing victims of securities fraud. Founded by the prominent attorney Abraham L. Pomerantz, the firm has spent decades advocating for shareholders' rights and holding corporations accountable for wrongful conduct. In its long history, Pomerantz has successfully secured numerous multimillion-dollar settlements on behalf of class members.

The investigation seeks to ascertain whether Argenx and its officers engaged in any fraudulent activities or misleading practices that could have adversely affected their investors. Potentially impacted investors are encouraged to consider joining the class action, a legal recourse designed to provide collective representation and pursue justice for those affected by corporate mismanagement.

Argenx’s situation raises crucial questions about accountability within the pharmaceutical industry, especially when it comes to the communication of trial results and the integrity of clinical research. Transparency with investors and the public is vital, particularly given the high stakes involved in drug development and the expectations investors place on the companies they support.

As this situation unfolds, it will be essential for affected investors to remain informed about their rights and the potential avenues for recovery. Pomerantz LLP is committed to providing the necessary guidance and support to those looking to navigate this complex landscape of securities law and corporate governance.

In conclusion, the ongoing investigation into Argenx SE by Pomerantz Law Firm highlights significant concerns within the sphere of medical research and investor relations. As more details emerge, stakeholders will be keen to watch how this case develops and the potential implications it may have for both Argenx and its investors.